Category: cancer biology

1st retraction for cancer researcher who doctored data in 11 studies

LeukemiaA cancer journal has retracted a paper co-authored by a researcher who falsified or fabricated data in 11 studies, according to an investigation by the Office of Research Integrity (ORI).

In December 2015, an ORI probe into the work of Girija Dasmahapatra concluded that he had

…duplicated, reused, and/or relabeled Western blot panels and mouse images and claimed they represented different controls and/or experimental results…

Dasmahapatra left the Virginia Commonwealth University (VCU) in July 2015.

Here’s the retraction notice, issued in April 2016: Continue reading 1st retraction for cancer researcher who doctored data in 11 studies

Author, among others, loses four papers for “compromised” peer review

Annals of human geneticsJournals have retracted four papers from an author after uncovering evidence the peer review process had been compromised. Three papers have all common authors. 

In one notice, issued last month, Annals of Human Genetics said it had reason to believe the paper had been reviewed by unqualified reviewers. Last year, another journal, Molecular Biology Reports, pulled two papers by the same group — all based at the China Medical University in Shenyang — all for peer-review issues. Additionally, Molecular Biology Reports also retracted another paper co-authored by Peng Liu last year, which did not include her other colleagues on the three other papers. All papers describe the epigenetic changes — modifications in expressions of genes — that may underlie cancer.

Here’s the retraction notice in the Annals of Human Genetics, published June 27: Continue reading Author, among others, loses four papers for “compromised” peer review

Researcher committed misconduct “recklessly,” says investigation

American Journal of Physiology Renal PhsyiologyA physiology journal has retracted a paper after an institutional investigation found that portions of the work had been falsified by the first author.

According to the notice issued by the American Journal of Physiology – Renal Physiology (AJP), the last author initiated the investigation at the University of Houston in Texas, which found the first author — Mousa Abkhezr — to be guilty of falsifying and duplicating images. 

We’ve obtained a copy of the investigation report, which concluded that Abkhezr committed misconduct “recklessly,” and the paper must be retracted. Although the report noted that Abkhezr argued that the problems stemmed from an honest error, the investigation committee ruled that data from the retracted paper cannot be included in his doctoral thesis.

The last author told us there is a separate ongoing “academic honesty enquiry” into Abkhezr’s dissertation. 

Here’s the retraction notice: Continue reading Researcher committed misconduct “recklessly,” says investigation

Investigation raises questions about top cancer researcher’s work

Journal of Pathology

A prominent pancreatic cancer researcher has lost a meeting abstract and corrected a Nature paper following an institutional investigation.

Queen Mary University of London determined that, in an abstract by Thorsten Hagemann, “elements of the study summarised by this abstract are not reliable.” Hagemann has recently issued a correction to a 2014 Nature paper he co-authored, which also cited the Queen Mary University of London (QMUL) investigation, noting there was “reason to question the provenance of the data.”

Hagemann is currently the medical director of Immodulon Therapeutics, and has long been recognized for his work in the field, including a three-year grant of £180,000 from the Pancreatic Cancer Research Fund in 2013.

Here’s the retraction notice from the The Journal of Pathology, regarding an abstract from the 7th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland: Continue reading Investigation raises questions about top cancer researcher’s work

JAMA: No plan to pull elephant-cancer risk paper after PETA protest

JAMAJAMA has decided not to retract an article about cancer risk in elephants after receiving a request to do so from an animal rights group.

People for the Ethical Treatment of Animals (PETA) recently protested the 2015 paper, which found that higher levels of a tumor suppressor gene could explain why elephants have a lower risk of cancer. According to PETA, the paper contained inaccurate information that could be used to justify inhumane treatment of elephants. At the time, the journal told us it considers all calls for retraction.

In an email sent to a representative of PETA over the weekend, Howard Bauchner, Editor in Chief at JAMA and The JAMA Network, wrote: Continue reading JAMA: No plan to pull elephant-cancer risk paper after PETA protest

Two journals retracting papers from University of Malaya featuring widely criticized figures

The image that excited twitter: Figure 6 from the Scientific Reports paper
The image that excited Twitter

One journal has retracted a paper containing images that recently raised suspicions of obvious duplications, and another journal is planning to do the same.

Scientists first leveled accusations against the newly retracted paper in Scientific Reports, along with two others by the same researchers, earlier this month on Twitter. One other journal — PeerJ — has announced that it plans to retract one of the questioned papers, as well. The third paper, in Frontiers in Pharmacology, bears an expression of concern.

It was unusually quick action on the part of the journals, as well as the authors’ host institution, the University of Malaya, which announced last week the authors had manipulated figures in all three papers, along with one other.

Here’s today’s retraction notice from Scientific Reports for “Novel piperazine core compound induces death in human liver cancer cells: possible pharmacological properties:”

Continue reading Two journals retracting papers from University of Malaya featuring widely criticized figures

Highly cited cancer researcher logs 8th, 9th retractions

Bharat Aggarwal
Bharat Aggarwal

Bharat Aggarwal, a highly cited cancer researcher who retired last year from MD Anderson, has logged two retractions following an investigation into his work, bringing his total to nine.

Aggarwal has threatened to sue us in the past, and told us that MD Anderson has been investigating his work. Earlier this year, Biochemical Pharmacology retracted seven studies of which he is the only common author, noting the “data integrity has become questionable.” Now, he’s earned two more retractions in Molecular Pharmacology, both for “inappropriate” or “unacceptable” image manipulation.

Both of the notices are paywalled (tsk, tsk). Here’s one for “Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells:” Continue reading Highly cited cancer researcher logs 8th, 9th retractions

Seventh retraction appears for cancer researcher who sued PubPeer commenters

sarkar
Fazlul Sarkar

Fazlul Sarkar, who sued PubPeer commenters for criticizing his work, has logged two more retractions, bringing his total to seven.

The two retractions appear in the Journal of Cellular Physiology, and follow five others released last week by another Wiley journal, Journal of Cellular Biochemistry. All notices mention an investigation at Wayne State University, where Sarkar is on the faculty.

Here’s the notice for “Activated K-Ras and INK4a/Arf Deficiency Promote Aggressiveness of Pancreatic Cancer by Induction of EMT Consistent With Cancer Stem Cell Phenotype:” Continue reading Seventh retraction appears for cancer researcher who sued PubPeer commenters

Researcher suing PubPeer commenters earns 5 retractions following investigation

sarkar
Fazlul Sarkar

An investigation at Wayne State University has prompted five retractions for a scientist who is suing PubPeer commenters after they criticized his work on the site.

The investigation into Fazlul Sarkar and his co-authors found that the papers contain images that were “inappropriately manipulated” or “inappropriately re-used and re-labeled.” All five retraction notices are from the Journal of Cellular Biochemistry.

Here’s the retraction notice for “Concurrent inhibition of NF-κB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer:

Continue reading Researcher suing PubPeer commenters earns 5 retractions following investigation

Images that raised eyebrows flagged by another journal; Malaysian gov’t investigates

Screen Shot 2016-06-15 at 9.17.15 AMMultiple investigations have been launched into allegations of blatant duplications by a research group in Malaysia.

Last week, users alleged on Twitter that three papers by the same team included pictures of cells that were copied and pasted. First author Nima Samie, affiliated with University of Malaya in Malaysia, denied the accusations — but both the Malaysian government and now two journals sees cause for further investigation.

Frontiers in Pharmacology published an expression of concern this morning:

Continue reading Images that raised eyebrows flagged by another journal; Malaysian gov’t investigates